The data indicated that all analyzed SLCO genes exhibited significantly increased expression levels (and/or were more often detectable) in cancer compared with benign tissue samples (FDR ranging from 0.038 for SLCO2B1 to 5.3 × 10−12 for SLCO3A1 and SLCO4A1, respectively). This evidence concerns the gene SLCO4A1 and cancer.